Sign up
Pharma Capital

AuMake International calls for trading pause pending business update

The halt will remain in place until Wednesday 10th January 2018.
1515367383_asx.jpg
The company's shares are in pre-open

AuMake International Ltd (ASX:AU8) has been granted a trading halt by the ASX this morning, pending details on the current entitlement offer and a business update.

AuMake shares last traded at $0.53, and the current capital raising program is fully-underwritten, but priced at $0.63.

The company is selling its products into China.

The halt will remain in place until the opening of trade on Wednesday 10th January 2018, or earlier if an announcement is made to the market.



Register here to be notified of future AU8 Company articles
View full AU8 profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.